Last reviewed · How we verify
Anti-BCMA CAR-NK Cells
At a glance
| Generic name | Anti-BCMA CAR-NK Cells |
|---|---|
| Sponsor | Xinqiao Hospital of Chongqing |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases (EARLY_PHASE1)
- Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases (EARLY_PHASE1)
- FT576 in Subjects With Multiple Myeloma (PHASE1)
- Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease (EARLY_PHASE1)
- An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy (EARLY_PHASE1)
- Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma (NA)
- Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-BCMA CAR-NK Cells CI brief — competitive landscape report
- Anti-BCMA CAR-NK Cells updates RSS · CI watch RSS
- Xinqiao Hospital of Chongqing portfolio CI